Sara Tolaney, ESMO 2022: AMEERA-3 phase 2 study – Amcenestrant vs. endocrine treatment in patients with endocrine-resistant ER+/HER2− advanced breast cancer
Amcenestrant is an optimized oral selective ER degrader (SERD), which is being investigated in the AMEERA-3 (NCT04059484), an open-label phase II randomized study. In this touchONCOLOGY interview, Dr Sara Tolaney (Dana-Farber Cancer Institute, and Brigham and Women’s Hospital, Boston, MA, USA) discusses the phase II study, investigating amcenestrant versus endocrine treatment of physician’s choice in patients with endocrine-resistant ER+/HER2− advanced breast cancer.
The abstract entitled ‘AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2− advanced breast cancer (aBC)‘ Abstract LBA14, was presented at European Society for Medical Oncology (ESMO) 2022.
Catch up on Dr Sara Tolaney’s ESMO 2022 clinical trial highlights in breast cancer
Questions:
- What is amcenestrant and what is the rationale for its use in the treatment of locally advanced or metastatic, estrogen receptor (ER)–positive, HER2-negative breast cancer? (0:13)
- What were the aims, design and eligibility criteria of the AMEERA-3 clinical trial? (0:45)
- What were the primary and secondary endpoints and how well were they achieved? (1:57)
- Why do you think amcenestrant failed to meet the primary endpoint in this study? (3:26)
- What will be the focus of further clinical development of amcenestrant in breast cancer? (5:06)
Disclosures: Sara Tolaney is a consultant for Novartis, Pfizer, Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Sanofi, Bristol Myers Squibb, Seattle Genetics, Odonate Therapeutics, CytomX Therapeutics, Daiichi Sankyo, Athenex, Gilead, Mersana, Certara, Ellipses Pharma, 4D Pharma, OncoSec Medical Inc., BeyondSpring Pharmaceuticals, OncXerna, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, ARC Therapeutics, Infinity Therapeutics, Chugai Pharmaceuticals, Myovant, Zetagen, and Umoja Biopharma; and also receives grant/research support from Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, NanoString Technologies, Cyclacel, Nektar, Gilead, Sanofi, and Seattle Genetics.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.
